Iaso Ventures

Prudentia Sciences is a platform enables AI-powered Asset Diligence and Valuation to De-Risk Investment in Drug Development.

Axonis Therapeutics is a biotechnology company focused on developing therapies for neurological disorders by targeting KCC2, a key mediator of inhibition in the brain. The company utilizes a proprietary discovery engine centered on the neuron-specific K-Cl cotransporter (KCC2) to address various conditions, including epilepsy and pain, as well as other central nervous system pathologies. By harnessing breakthrough research from institutions such as Boston Children’s Hospital, Harvard, and Laval University, Axonis aims to enhance the lives of individuals affected by these disorders through improved modulation of neuronal inhibition.

Scaffold Therapeutics is a venture-backed drug development company focused on creating ribonucleic acid (RNA) therapies for cancer. By leveraging machine learning technology and current research data, the company aims to accelerate the discovery of new small-molecule oncology therapeutics. Scaffold Therapeutics specializes in understanding specific writer-reader-eraser pathways, which enhances insights into pathway biology. This approach provides medical professionals with real-time direction and aligns experimental research with project objectives, ultimately contributing to the development of innovative treatments for various disease areas.

Zafrens is a drug discovery company based in San Diego, California, founded in 2021. The company specializes in developing life sciences products that facilitate the comprehensive characterization of diverse cell populations. Its innovative platform focuses on generating insights at the intersection of biology, chemistry, and engineering. Zafrens employs a resolution approach to study interactions between cells and drugs by directly mapping the molecular states of individual cells. The extensive volume of curated experimental data generated by Zafrens is utilized to train artificial intelligence models aimed at advancing drug discovery. Additionally, the company possesses internal expertise in T cell immunotherapies and ribonucleic acid regulation, leveraging its proprietary data and experimental capabilities to support advancements in the medical industry.

Pragma Bio is a biotechnology company focused on developing microbiome-based therapies for cancer and autoimmune diseases. Founded in 2018 in Millbrae, California, by Peter McCaffrey, Kovi Bessoff, Ayin Vala, and Kareem Barghouti, the company utilizes proprietary genomic sequencing, artificial intelligence, and synthetic biology techniques to identify biomarkers and therapeutics for complex immunologic disorders. Its innovative platform aggregates extensive public and private data to create a microbiome database, enabling the discovery of connections between biologically relevant data. By using this analytical approach, Pragma Bio aims to identify novel biomarkers that can help stratify patient risk and predict clinical outcomes. The company emphasizes the importance of understanding the gut-immune axis and employs machine learning to enhance the drug discovery process, offering a more efficient alternative to traditional methods and aiming to deliver improved medicines to patients more rapidly and cost-effectively.

ClexBio is a pre-clinical stage regenerative medicine company focused on developing innovative bioengineered human blood vessels for transplant. Utilizing advanced tissue engineering and single-cell techniques, the company combines its proprietary hydrogel technology with bio-fabrication methods to produce scalable, high-throughput tissue generation. ClexBio holds patents for a novel approach to creating biocompatible hydrogels and for growing large tissues from healthy human cells in complex geometric shapes. This technology enables researchers to generate patient-specific blood vessels for both preclinical and clinical applications, positioning ClexBio at the forefront of regenerative medicine.

Altimate Health is at the forefront of precision psychiatry, focusing on improving treatment outcomes for patients with serious mental illnesses. By integrating advances in neuroscience, data analytics, and health economics, Altimate Health enables healthcare providers, insurers, and pharmaceutical companies to pinpoint the most effective treatments tailored to individual patient needs. Their approach combines artificial intelligence with precision medicine to enhance access to care and optimize health outcomes. This innovative platform not only aims to improve patient care but also seeks to reduce healthcare costs significantly, potentially saving the system hundreds of billions of dollars.

Celeri Health, Inc. is a company that specializes in providing patient-reported outcome (PRO) tools designed to evaluate and enhance the everyday experiences of patients. Founded in 2018 and based in Paoli, Pennsylvania, Celeri Health offers a software platform that allows healthcare professionals to screen patients and track outcomes using tools derived from the NIH PROMIS system. This platform integrates with electronic health record (EHR) systems to optimize health information management and improve documentation processes. By facilitating real-time data capture and enhancing patient engagement, Celeri Health aims to support healthcare providers in promoting wellness, alleviating pain, and restoring function for their patients.

Deep 6 AI Inc. operates an artificial intelligence-based platform that facilitates patient matching for clinical trials. The software analyzes both structured data, such as ICD-10 codes, and unstructured clinical data, including doctor’s notes and pathology reports, to extract critical clinical data points like symptoms, diagnoses, and treatments. By employing artificial intelligence and natural language processing, Deep 6 AI transforms fragmented medical documents into unified patient graphs that allow for more accurate matching of patients to complex clinical trial criteria. The platform not only identifies patients whose conditions may not be explicitly documented in medical records but also enhances the recruitment process by finding patients who more closely align with trial requirements. Founded in 2013 and based in Pasadena, California, Deep 6 AI was previously known as Deep 6 Analytics, LLC before rebranding in March 2017.

Soovu Labs, Inc. is a Seattle-based company that specializes in developing innovative, drug-free solutions for chronic pain relief. Founded by two pain management physicians from the University of Washington Medical Center, the company has created a wearable device that utilizes pulsed heat technology to alleviate lower back and menstrual pain. The device, which is clinically proven and FDA registered, emits precise heat pulses to disrupt pain signals and provide soothing relief. In addition to the wearable, Soovu Labs offers a companion application that delivers personalized coaching, movement exercises, and relaxation techniques to enhance the overall pain management experience. With a focus on helping individuals recover from injuries and manage chronic and arthritic pain, Soovu Labs aims to improve quality of life and workplace productivity without relying on pharmaceuticals.

Catena Biosciences is a biotechnology company focused on advancing protein conjugation technology to develop novel therapeutics for autoimmune disorders, oncology, and vaccine development. The company specializes in the efficient and selective attachment of proteins using natural amino acids, specifically tyrosine and cysteine. This innovative approach allows researchers to create biologic structures more rapidly than traditional methods, enhancing the potential for medical research and treatment options in various disease areas. Catena Biosciences aims to contribute significantly to the field of biomedicine through its cutting-edge technology and applications.